PT3106176T - Compostos de alumínio para utilização em produtos terapêuticos e vacinas - Google Patents

Compostos de alumínio para utilização em produtos terapêuticos e vacinas

Info

Publication number
PT3106176T
PT3106176T PT161830765T PT16183076T PT3106176T PT 3106176 T PT3106176 T PT 3106176T PT 161830765 T PT161830765 T PT 161830765T PT 16183076 T PT16183076 T PT 16183076T PT 3106176 T PT3106176 T PT 3106176T
Authority
PT
Portugal
Prior art keywords
vaccines
aluminum compounds
therapeutic products
therapeutic
products
Prior art date
Application number
PT161830765T
Other languages
English (en)
Inventor
Möhlen Michael
Weber Michael
Wruss Jürgen
Schlegl Robert
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47294919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3106176(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/054387 external-priority patent/WO2013135274A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of PT3106176T publication Critical patent/PT3106176T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT161830765T 2011-12-06 2012-12-06 Compostos de alumínio para utilização em produtos terapêuticos e vacinas PT3106176T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11192230 2011-12-06
PCT/EP2012/054387 WO2013135274A1 (en) 2012-03-13 2012-03-13 Aluminium compounds for use in therapeutics and vaccines

Publications (1)

Publication Number Publication Date
PT3106176T true PT3106176T (pt) 2017-12-20

Family

ID=47294919

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171855265T PT3269386T (pt) 2011-12-06 2012-12-06 Compostos de alumínio para utilização em terapêuticas e vacinas
PT161830765T PT3106176T (pt) 2011-12-06 2012-12-06 Compostos de alumínio para utilização em produtos terapêuticos e vacinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT171855265T PT3269386T (pt) 2011-12-06 2012-12-06 Compostos de alumínio para utilização em terapêuticas e vacinas

Country Status (16)

Country Link
EP (5) EP4400115A3 (pt)
CY (1) CY1119927T1 (pt)
DE (1) DE202012012768U1 (pt)
DK (6) DK3785730T3 (pt)
ES (3) ES2987623T3 (pt)
FI (1) FI3785730T3 (pt)
HR (1) HRP20171871T1 (pt)
HU (1) HUE037325T2 (pt)
LT (1) LT3106176T (pt)
NO (1) NO3106176T3 (pt)
PL (2) PL3106176T3 (pt)
PT (2) PT3269386T (pt)
RS (1) RS56709B1 (pt)
SI (1) SI3106176T1 (pt)
SM (1) SMT201700607T1 (pt)
WO (1) WO2013083726A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56709B1 (sr) 2011-12-06 2018-03-30 Valneva Austria Gmbh Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX379510B (es) 2014-09-03 2025-03-10 Intervet Int Bv Coronavirus bovino atenuado y vacunas relacionadas.
EP4357355A3 (en) 2015-12-23 2024-09-25 Valneva SE Virus purification
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3609911B1 (en) 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
KR102757369B1 (ko) 2017-09-21 2025-01-20 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CA3106286A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
PH12021552736A1 (en) 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
AU2021230501A1 (en) * 2020-03-01 2022-10-27 Dynavax Technologies Corporation Coronavirus vaccines comprising a TLR9 agonist
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
US20230092650A1 (en) * 2020-03-01 2023-03-23 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
US12605442B2 (en) 2020-03-06 2026-04-21 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
PH12022552300A1 (en) * 2020-04-06 2023-12-11 Dynavax Tech Corp Cpg-adjuvanted sars-cov-2 virus vaccine
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
US20230398210A1 (en) * 2020-04-09 2023-12-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
US20240358812A1 (en) 2021-04-09 2024-10-31 Valneva Se Human metapneumovirus combination vaccine
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024153686A1 (en) 2023-01-18 2024-07-25 Valneva Austria Gmbh Process for virus production in a bioreactor
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4761372A (en) 1981-01-12 1988-08-02 New York University Mutant enterotoxin of E. coli
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5308835A (en) 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AUPO264096A0 (en) 1996-09-30 1996-10-24 Mclaughlin Geosurveys Pty Ltd. Value improvement of clays
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CN1142271C (zh) 1997-08-28 2004-03-17 第一制糖株式会社 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2009158284A2 (en) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
CN101734698B (zh) 2009-09-08 2013-01-09 东北大学 一种由含铝物料制备氧化铝的方法
RS56709B1 (sr) 2011-12-06 2018-03-30 Valneva Austria Gmbh Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama

Also Published As

Publication number Publication date
EP3106176A1 (en) 2016-12-21
CY1119927T1 (el) 2018-12-12
PT3269386T (pt) 2022-12-05
EP3269386A1 (en) 2018-01-17
DK201300194U1 (da) 2014-01-17
DK3785730T3 (da) 2024-05-06
NO3106176T3 (pt) 2018-03-10
HUE037325T2 (hu) 2018-08-28
ES2930458T3 (es) 2022-12-13
EP3785730A1 (en) 2021-03-03
EP3106176B1 (en) 2017-10-11
EP2788023B1 (en) 2016-11-02
EP3785730B1 (en) 2024-04-24
EP4400115A3 (en) 2024-10-23
LT3106176T (lt) 2018-01-10
DK3106176T3 (en) 2018-01-08
RS56709B1 (sr) 2018-03-30
HRP20171871T1 (hr) 2018-01-12
SI3106176T1 (en) 2018-04-30
PL3269386T3 (pl) 2022-12-05
ES2647882T3 (es) 2017-12-27
ES2987623T3 (es) 2024-11-15
EP2788023A1 (en) 2014-10-15
DK201300193U1 (da) 2014-01-17
EP3269386B1 (en) 2022-09-14
PL3106176T3 (pl) 2018-03-30
WO2013083726A1 (en) 2013-06-13
EP4400115A2 (en) 2024-07-17
DE202012012768U1 (de) 2014-01-21
DK3269386T3 (da) 2022-10-24
FI3785730T3 (fi) 2024-05-06
DK2788023T3 (en) 2016-12-19
SMT201700607T1 (it) 2018-01-11

Similar Documents

Publication Publication Date Title
HRP20171871T1 (hr) Spojevi aluminija za uporabu u terapeutskim proizvodima i cjepivima
BR302012003126S1 (pt) Configuração aplicada em empunhadura para intrumento médico
IL228649B (en) Immunogenic compositions for use in therapy
PT2739268T (pt) Método e formulação para inalação
IL247311A0 (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
PL3033950T3 (pl) Pręty do zastosowania w wyrobach do palenia
BR302012002887S1 (pt) Configuração aplicada em garrafa para cuidado pessoal
PT2858633T (pt) Terapias sinérgicas de canabidiol em hipotermia para a neuroproteção
BR112015002783A2 (pt) método e dispositivo para manipular artigos de higiene
SG10201606161UA (en) Albumin Formulation and Use
IL229381B (en) Brilacitidine and its results for use in the treatment of mucositis
BR112014009111A2 (pt) embalagem para produtos absorventes descartáveis e métodos relacionados
GB201218084D0 (en) Novel compounds and methods for use in medicine
BR112014009421A2 (pt) combinação terapêutica e método para tratamento
CO6781476A2 (es) Dispositivo modeable para terapia de lesiones y método
IL231096A0 (en) 2-converted thiazoles (chroman-6-yloxy) and their use as pharmaceutical preparations
IL232809A (en) Carboxamides are preserved in position 2 isothiazolopyridine-2-carboxamides and used as drugs
PH12014500542A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
BRDI7103877S (pt) Configuração aplicada em expositor para produtos de beleza
GB201121833D0 (en) Aluminium compounds for use in therapeutics and vaccines
IL229936B (en) Albumin formulation and use
ES1074387Y (es) Aparato aplicador de producto para estetica y electromedicina
BRDI7105248S (pt) Configuração aplicada em andador
GB201112578D0 (en) Pharmaceutical preparation and use
BR302012001635S1 (pt) Configuração aplicada em frasco para bebidas em geral